Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

This study has been completed.
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
AbbVie
ClinicalTrials.gov Identifier:
NCT01577550
First received: April 10, 2012
Last updated: November 15, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)